Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.
Neoadjuvant (primary systemic) treatment is the standard treatment for locally advanced breast cancer and a standard option for primary operable disease. Because of new treatments and new understandings of breast cancer, however, recommendations published in 2003 regarding neoadjuvant treatment for operable disease required updating. Therefore, a second international panel of representatives of a number of breast cancer clinical research groups was convened in September 2004 to update these recommendations. As part of this effort, data published to date were reviewed critically and indications for neoadjuvant treatment were newly defined.
Kaufmann
Manfred
M
Department of Obstetrics and Gynecology, J.W. Goethe-University Hospital, Frankfurt, Germany. M.Kaufmann@em.uni-frankfurt.de
Hortobagyi
Gabriel N
GN
Goldhirsch
Aron
A
Scholl
Suzy
S
Makris
Andreas
A
Valagussa
Pinuccia
P
Blohmer
Jens-Uwe
JU
Eiermann
Wolfgang
W
Jackesz
Raimund
R
Jonat
Walter
W
Lebeau
Annette
A
Loibl
Sibylle
S
Miller
William
W
Seeber
Sigfried
S
Semiglazov
Vladimir
V
Smith
Roy
R
Souchon
Rainer
R
Stearns
Vered
V
Untch
Michael
M
von Minckwitz
Gunter
G
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000601:surgery; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy; D018579:Patient Selection; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis
D018931:Antineoplastic Agents, Hormonal; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone